AMH has long occupied a central place in reproductive endocrinology. Secreted by small growing follicles in the ovary, the hormone serves as a circulating proxy for the size of the resting follicle pool, the reserve that determines both fertility potential and the trajectory toward menopause. In assisted reproduction clinics worldwide, AMH measurements guide ovarian stimulation protocols and counseling about expected response. Yet the hormone’s clinical usefulness in midlife women has remained constrained by two practical problems. First, most existing reference ranges were derived from populations of reproductive-age women, so precise age-specific values for women over 35, and especially those navigating the menopausal transition, have often been lacking. Second, conventional immunoassays can lose analytical sensitivity at the very low concentrations characteristic of late reproductive life, making subtle but clinically meaningful changes difficult to detect and quantify.

To address both limitations, a research team led by Professor Yingying Qin of Shandong University, in collaboration with Professor Ruimin Zheng of the National Center for Women and Children’s Health, drew on a large nationwide cohort of Chinese women aged 35 to 55. By applying an ultrasensitive AMH assay, the investigators were able to measure the hormone with greater precision in precisely the age range where levels approach the floor of detection. This proved particularly important among women aged 44 to 49, a phase the researchers characterize as one of near-depletion, when conventional assays may return values so low that differences between individuals are obscured. The resulting age-specific percentile table, published online on August 17, 2026, in the Chinese Medical Journal, functions as a calibrated chart: a clinician can take a woman’s exact age and her AMH value and locate where she sits relative to the distribution of her peers, seeing at a glance whether her ovarian reserve appears well ahead of or lagging behind the norm for her age.

The percentile framework is more than a descriptive atlas. The team evaluated its clinical utility in a hospital-based care cohort, focusing on women aged 35 to 40 who still planned to conceive. Among these patients, those whose baseline AMH fell below the 10th percentile for their age carried a substantially higher risk of progressing to severely diminished ovarian reserve, defined in the study as an AMH concentration below 0.25 nanograms per milliliter, compared with women whose values sat within the normal percentile range. That distinction matters for fertility counseling. A single AMH reading, interpreted against an age-matched distribution rather than a one-size-fits-all cutoff, can give a woman in her late thirties a quantitative, individualized signal about how quickly her reserve may be declining, informing decisions about the timing of pregnancy attempts or the pursuit of assisted reproduction.

The study’s ambitions extend beyond fertility. Perimenopausal symptoms, particularly vasomotor complaints such as hot flashes and night sweats, are among the most common and most under-recognized problems in routine midlife care, yet they are typically assessed only through subjective questionnaires. The researchers found that among women aged 35 to 55, lower AMH levels were associated with a greater likelihood of more severe perimenopausal symptoms, with the relationship most evident for vasomotor symptoms. This raises the possibility that AMH could serve as an objective biomarker to complement symptom inventories, helping clinicians stratify patients by the likely intensity of their transition and tailor management accordingly, including consideration of hormone replacement therapy when clinically appropriate. The authors are careful to frame this as an association that supports more integrated care rather than a deterministic prediction; symptom experience varies widely among women with similar hormone profiles, and AMH would supplement, not replace, careful clinical assessment.

A third application tested in the study concerns the diagnosis of menopause itself. Clinically, menopausal status is usually inferred from menstrual history together with hormone measurements, but follicle-stimulating hormone and estradiol can fluctuate dramatically during the transition, sometimes producing ambiguous results. Comparing AMH levels between premenopausal and postmenopausal women, the team observed a cliff-like drop, with mean values of 0.187 nanograms per milliliter in premenopausal participants versus 0.043 nanograms per milliliter in those who were postmenopausal. The magnitude of that separation is striking at the group level, but the hormone’s power to classify any individual woman proved moderate, with an overall discriminative performance of around 0.7 on the area under the receiver operating characteristic curve, a standard measure of diagnostic accuracy in which 0.5 indicates chance performance and 1.0 indicates perfect classification.

That moderate AUC carries an important practical message: AMH by itself is not sufficient as a stand-alone diagnostic test for menopause. Menopause remains, fundamentally, a retrospective clinical diagnosis anchored in twelve consecutive months of amenorrhea. However, the study suggests that extremely low AMH values, measured with an ultrasensitive assay, can still provide useful supportive information in clinically challenging situations, for example when a woman’s menstrual pattern is disrupted by contraception or other conditions and her FSH and estradiol results fluctuate across the diagnostic threshold. In such cases, a near-undetectable AMH reading adds a piece of biological evidence that, combined with the rest of the clinical picture, can help clinicians assess where a patient stands in the transition.

The technical achievement underlying these applications lies in the assay itself. At the low concentrations typical of women in their mid-to-late forties, conventional platforms approach their limits of quantification, and small analytical imprecision can translate into large relative errors. An ultrasensitive assay extends the measurable range downward, allowing the near-depletion phase to be characterized rather than lumped into a single undetectable category. That analytical gain is what makes an age-specific percentile table feasible across the full 35-to-55 span: without reliable measurement at the low end, the lower percentiles for older age bands would be statistically unstable and clinically uninterpretable. The nationwide cohort design further strengthens the reference values by capturing the geographic and demographic breadth of the Chinese population, an important consideration given that AMH distributions can vary across ethnic groups and study settings.

Taken together, the new scale addresses practical clinical gaps across both the late reproductive and perimenopausal stages, and the researchers frame its contribution around three integrated goals. Earlier identification means recognizing women at higher risk of low ovarian reserve sooner, providing quantitative support for fertility planning in later reproductive age. Better management means combining AMH profiling with symptom assessment to support more precise handling of perimenopausal complaints and improve quality of life in midlife. Supportive diagnosis means acknowledging that while AMH alone is not an ideal menopause test, very low values measured ultrasensitively can assist clinicians in assessing menopausal status, particularly in complex cases where other reproductive hormones are difficult to interpret. The work was supported by the National Natural Science Foundation of China, the National Key Research and Development Program of China, and several provincial and institutional funders, reflecting the scale of investment in reproductive aging research in China.

For women’s health practice, the study signals a shift toward treating the menopausal transition with the same quantitative rigor long applied to earlier reproductive life. An age-calibrated AMH reference scale gives clinicians a common language for discussing ovarian reserve with patients in their thirties, forties, and fifties, replacing vague reassurances or alarming single cutoffs with a percentile position that evolves with age. It also opens the door to longitudinal use: repeated measurements plotted against the age-specific curve could, in principle, reveal whether an individual woman’s reserve is declining on a typical trajectory or at an accelerated pace, though the current study establishes the cross-sectional framework rather than validating serial monitoring. As ultrasensitive assays become more widely available, the approach developed by Qin, Zheng, and colleagues may prompt parallel reference studies in other populations, a necessary step before the Chinese percentile tables are applied globally. What the study already demonstrates is that the hormonal signature of reproductive aging can be measured, mapped, and translated into clinical decision support across the full arc of midlife, from fertility planning to symptom management to the supportive assessment of menopause itself.

Subject of Research: Age-specific anti-Müllerian hormone reference values for reproductive aging in Chinese women

Article Title: A new scale for reproductive aging in Chinese women based on ultra-sensitive AMH testing

Article References: A new scale for reproductive aging in Chinese women based on ultra-sensitive AMH testing. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: AMH, anti-Müllerian hormone, ovarian reserve, reproductive aging, menopause, perimenopause, ultrasensitive assay, fertility, vasomotor symptoms, hormone replacement therapy, Chinese Medical Journal, women's health